Woodline Partners LP Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Woodline Partners LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$83.14 - $145.99 $10.3 Million - $18 Million	123,502 New	123,502 $18 Million
Q4 2021 Feb 14, 2022	SELL	$99.73 - $148.48 $4.04 Million - $6.02 Million	-40,515 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$98.85 - $138.91 $8.1 Million - $11.4 Million	-81,893 Reduced 66.9%	40,515 $5.63 Million
Q2 2021 Aug 16, 2021	SELL	$65.78 - $105.02 $4.33 Million - $6.92 Million	-65,848 Reduced 34.98%	122,408 $11.9 Million
Q1 2021 May 17, 2021	BUY	$64.07 - $91.75 $12.1 Million - $17.3 Million	188,256 New	188,256 $12.9 Million
Q3 2020 Nov 16, 2020	SELL	$59.04 - $77.95 $3.61 Million - $4.77 Million	-61,221 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$29.01 - $74.23 $1.78 Million - $4.54 Million	61,221 New	61,221 $4.48 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.